Article Text
PDF
Statistics from Altmetric.com
Q In postmenopausal women with osteoporosis, does a once yearly intravenous infusion of zoledronic acid reduce the incidence of fractures?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Rheumatology ★★★★★★★ Endocrine ★★★★★★☆ Geriatrics ★★★★★★☆
METHODS
Design:
randomised placebo controlled trial (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly [HORIZON]).
Allocation:
not concealed.*
Blinding:
blinded (outcome assessors).*
Follow-up period:
36 months.
Setting:
clinics in 25 countries in Europe, North and Latin America, Australia, and Asia.
Patients:
7765 postmenopausal women (mean age 73 y) with a bone mineral density T score ⩽2.5 at the femoral neck, with or without vertebral fractures, or with a T score ⩽1.5 and ⩾2 mild or 1 moderate vertebral fractures. Women were grouped as stratum 1 (n = 6113) if they were not taking …
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Linked Articles
- Glossary